Prelude Therapeutics annual operating margin
2024
2025
Prelude Therapeutics's operating margin was −861.33% for fiscal 2025.
View full Prelude Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −861.33% | +1134.58 pp |
| 2024 | 2024-12-31 | −1,995.91% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −270.93% | +874.93 pp |
| Q1 2026 | 2026-03-31 | −309.54% | — |
| Q4 2025 | 2025-12-31 | −307.59% | — |
| Q3 2025 | 2025-09-30 | −314.12% | — |
| Q3 2024 | 2024-09-30 | −1,145.87% | — |
Across the available reported history, Prelude Therapeutics's operating margin increased from −1,995.91% to −861.33%, a change of +1134.58 percentage points. The latest reported quarter, Q2 2026, shows −270.93%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics filings at SEC.gov ↗